A study found that there is no significant difference in the risk of kidney failure among three Anti-VEGF drugs. The study analyzed data on the three drugs and concluded that they have similar risk profiles for kidney failure. The use of cookies for analytics and advertising on the site was also mentioned, with users agreeing to their use by continuing to use the site. More information on the use of cookies can be found in the Cookie Policy and Settings.
Source link
No substantially different relative risk for kidney failure among three Anti-VEGF Drugs, finds study
